Chronic pneumonitis of infancy

Summary

Chronic pneumonitis of infancy (MONDO:0019621) is a disease. A subtype of interstitial lung disease specific to infancy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 13

Clinical features

Signs & symptoms

Clinical features (HPO)

13 HPO clinical features (Orphanet curated; top 13 by frequency):

HPO ID	Term	Frequency
HP:0001508	Failure to thrive	Frequent (30-79%)
HP:0002207	Diffuse reticular or finely nodular infiltrations	Frequent (30-79%)
HP:0002883	Hyperventilation	Frequent (30-79%)
HP:0012418	Hypoxemia	Frequent (30-79%)
HP:0012735	Cough	Frequent (30-79%)
HP:0025179	Ground-glass opacification on pulmonary HRCT	Frequent (30-79%)
HP:0032341	Reduced forced vital capacity	Frequent (30-79%)
HP:0000961	Cyanosis	Occasional (5-29%)
HP:0001945	Fever	Occasional (5-29%)
HP:0002098	Respiratory distress	Occasional (5-29%)
HP:0002789	Tachypnea	Occasional (5-29%)
HP:0030864	Intercostal retractions	Occasional (5-29%)
HP:0100721	Mediastinal lymphadenopathy	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic pneumonitis of infancy
Mondo ID	MONDO:0019621
Orphanet	91359
ICD-11	1821220054
SNOMED CT	708026002
UMLS	C3872848
MedGen	846677
GARD	0019166
Is cancer (heuristic)	no

Also known as: CPI

Disease family

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › interstitial lung disease specific to childhood › primary interstitial lung disease specific to childhood › interstitial lung disease specific to infancy › chronic pneumonitis of infancy

Related subtypes (4): pulmonary interstitial glycogenosis, neuroendocrine cell hyperplasia of infancy, persistent tachypnoe of infancy, cellular interstitial pneumonitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.